BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ji X, Li Z. Medicinal chemistry strategies toward host targeting antiviral agents. Med Res Rev 2020;40:1519-57. [PMID: 32060956 DOI: 10.1002/med.21664] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 González-Cardenete MA, Hamulić D, Miquel-Leal FJ, González-Zapata N, Jimenez-Jarava OJ, Brand YM, Restrepo-Mendez LC, Martinez-Gutierrez M, Betancur-Galvis LA, Marín ML. Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. J Nat Prod 2022. [PMID: 35969814 DOI: 10.1021/acs.jnatprod.2c00464] [Reference Citation Analysis]
2 Urvashi, Senthil Kumar JB, Das P, Tandon V. Development of Azaindole-Based Frameworks as Potential Antiviral Agents and Their Future Perspectives. J Med Chem 2022. [PMID: 35477274 DOI: 10.1021/acs.jmedchem.2c00444] [Reference Citation Analysis]
3 Karade SS, Kolesnikov A, Treston AM, Mariuzza RA. Identification of Endoplasmic Reticulum α-Glucosidase I from a Thermophilic Fungus as a Platform for Structure-Guided Antiviral Drug Design. Biochemistry 2022. [PMID: 35476408 DOI: 10.1021/acs.biochem.2c00092] [Reference Citation Analysis]
4 Nekoua MP, Mercier A, Alhazmi A, Sane F, Alidjinou EK, Hober D. Fighting Enteroviral Infections to Prevent Type 1 Diabetes. Microorganisms 2022;10:768. [DOI: 10.3390/microorganisms10040768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ilgova E, Galkin S, Khrenova M, Serebryakova M, Gottikh M, Anisenko A. Complex of HIV-1 Integrase with Cellular Ku Protein: Interaction Interface and Search for Inhibitors. Int J Mol Sci 2022;23:2908. [PMID: 35328329 DOI: 10.3390/ijms23062908] [Reference Citation Analysis]
6 Luo F, Zhou H, Chen X, Liu X, Chen X, Qian P, Wu X, Wang W, Zhang S. Synthesis of α-Aryl Primary Amides from α-Silyl Nitriles and Aryl Sulfoxides through [3,3]-Sigmatropic Rearrangement. Org Lett . [DOI: 10.1021/acs.orglett.2c00334] [Reference Citation Analysis]
7 Wang Z, Cherukupalli S, Xie M, Wang W, Jiang X, Jia R, Pannecouque C, De Clercq E, Kang D, Zhan P, Liu X. Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. J Med Chem 2022. [PMID: 35175760 DOI: 10.1021/acs.jmedchem.1c01758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tan S, Banwell MG, Ye WC, Lan P, White LV. The Inhibition of RNA Viruses by Amaryllidaceae Alkaloids: Opportunities for the Development of Broad-Spectrum Anti-Coronavirus Drugs. Chem Asian J 2022;:e202101215. [PMID: 35032358 DOI: 10.1002/asia.202101215] [Reference Citation Analysis]
9 Karade SS, Hill ML, Kiappes JL, Manne R, Aakula B, Zitzmann N, Warfield KL, Treston AM, Mariuzza RA. N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity. J Med Chem 2021;64:18010-24. [PMID: 34870992 DOI: 10.1021/acs.jmedchem.1c01377] [Reference Citation Analysis]
10 Sadeghian I, Heidari R, Sadeghian S, Raee MJ, Negahdaripour M. Potential of cell-penetrating peptides (CPPs) in delivery of antiviral therapeutics and vaccines. Eur J Pharm Sci 2021;169:106094. [PMID: 34896590 DOI: 10.1016/j.ejps.2021.106094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
11 Naidu SAG, Mustafa G, Clemens RA, Naidu AS. Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against RNA-Dependent RNA Polymerase Complex (nsp7/nsp8/nsp12) of SARS-CoV-2. J Diet Suppl 2021;:1-30. [PMID: 34850656 DOI: 10.1080/19390211.2021.2006387] [Reference Citation Analysis]
12 Unsal Tan O, Zengin M. Insights into the chemistry and therapeutic potential of acrylonitrile derivatives. Arch Pharm (Weinheim) 2021;:e202100383. [PMID: 34763365 DOI: 10.1002/ardp.202100383] [Reference Citation Analysis]
13 de Siqueira Santos S, Torres M, Galeano D, Sánchez MDM, Cernuzzi L, Paccanaro A. Machine Learning and Network Medicine approaches for Drug Repositioning for COVID-19. Patterns (N Y) 2021;:100396. [PMID: 34778851 DOI: 10.1016/j.patter.2021.100396] [Reference Citation Analysis]
14 Xu X, Zhang QY, Chu XY, Quan Y, Lv BM, Zhang HY. Facilitating Antiviral Drug Discovery Using Genetic and Evolutionary Knowledge. Viruses 2021;13:2117. [PMID: 34834924 DOI: 10.3390/v13112117] [Reference Citation Analysis]
15 Grazia Martina M, Vicenti I, Bauer L, Crespan E, Rango E, Boccuto A, Olivieri N, Incerti M, Zwaagstra M, Allodi M, Bertoni S, Dreassi E, Zazzi M, van Kuppeveld FJM, Maga G, Radi M. Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus, and Human Rhinoviruses. ChemMedChem 2021. [PMID: 34382337 DOI: 10.1002/cmdc.202100483] [Reference Citation Analysis]
16 Malik NP, Naz M, Ashiq U, Jamal RA, Gul S, Saleem F, Khan KM, Yousuf S. Oxamide Derivatives as Potent α ‐Glucosidase Inhibitors: Design, Synthesis, In Vitro Inhibitory Screening and In Silico Docking Studies. ChemistrySelect 2021;6:7188-201. [DOI: 10.1002/slct.202101709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Hall MD, Anderson JM, Anderson A, Baker D, Bradner J, Brimacombe KR, Campbell EA, Corbett KS, Carter K, Cherry S, Chiang L, Cihlar T, de Wit E, Denison M, Disney M, Fletcher CV, Ford-Scheimer SL, Götte M, Grossman AC, Hayden FG, Hazuda DJ, Lanteri CA, Marston H, Mesecar AD, Moore S, Nwankwo JO, O'Rear J, Painter G, Singh Saikatendu K, Schiffer CA, Sheahan TP, Shi PY, Smyth HD, Sofia MJ, Weetall M, Weller SK, Whitley R, Fauci AS, Austin CP, Collins FS, Conley AJ, Davis MI. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit. J Infect Dis 2021;224:S1-S21. [PMID: 34111271 DOI: 10.1093/infdis/jiab305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Ng YL, Salim CK, Chu JJH. Drug repurposing for COVID-19: Approaches, challenges and promising candidates. Pharmacol Ther 2021;228:107930. [PMID: 34174275 DOI: 10.1016/j.pharmthera.2021.107930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sabnis RW. Combination Therapy of RNA Interference and Small Molecules for Treating Hepatitis B Virus Infection. ACS Med Chem Lett 2021;12:858-9. [PMID: 34141056 DOI: 10.1021/acsmedchemlett.1c00103] [Reference Citation Analysis]
20 Zheng W, Wu H, Wang T, Zhan S, Liu X. Quercetin for COVID-19 and DENGUE co-infection: a potential therapeutic strategy of targeting critical host signal pathways triggered by SARS-CoV-2 and DENV. Brief Bioinform 2021:bbab199. [PMID: 34058750 DOI: 10.1093/bib/bbab199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 S AH, Pujar GV, Sethu AK, Bhagyalalitha M, Singh M. Dengue structural proteins as antiviral drug targets: Current status in the drug discovery & development. Eur J Med Chem 2021;221:113527. [PMID: 34020338 DOI: 10.1016/j.ejmech.2021.113527] [Reference Citation Analysis]
22 Musarra-Pizzo M, Pennisi R, Ben-Amor I, Mandalari G, Sciortino MT. Antiviral Activity Exerted by Natural Products against Human Viruses. Viruses 2021;13:828. [PMID: 34064347 DOI: 10.3390/v13050828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
23 Geraghty RJ, Aliota MT, Bonnac LF. Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. Viruses 2021;13:667. [PMID: 33924302 DOI: 10.3390/v13040667] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
24 Yang KC, Lin JC, Tsai HH, Hsu CY, Shih V, Hu CJ. Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control. Drug Deliv Transl Res 2021;11:1420-37. [PMID: 33748879 DOI: 10.1007/s13346-021-00965-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Su H, Xu Y, Jiang H. Drug discovery and development targeting the life cycle of SARS-CoV-2. Fundamental Research 2021;1:151-65. [DOI: 10.1016/j.fmre.2021.01.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
26 Adamson CS, Chibale K, Goss RJM, Jaspars M, Newman DJ, Dorrington RA. Antiviral drug discovery: preparing for the next pandemic. Chem Soc Rev 2021;50:3647-55. [PMID: 33524090 DOI: 10.1039/d0cs01118e] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 15.0] [Reference Citation Analysis]
27 Anasir MI, Zarif F, Poh CL. Antivirals blocking entry of enteroviruses and therapeutic potential. J Biomed Sci 2021;28:10. [PMID: 33451326 DOI: 10.1186/s12929-021-00708-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Reed JC, Solas D, Kitaygorodskyy A, Freeman B, Ressler DTB, Phuong DJ, Swain JV, Matlack K, Hurt CR, Lingappa VR, Lingappa JR. Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly. J Virol 2021;95:e00883-20. [PMID: 33148797 DOI: 10.1128/JVI.00883-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Huchting J. Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections. Antivir Chem Chemother 2020;28:2040206620976786. [PMID: 33297724 DOI: 10.1177/2040206620976786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Winnard PT Jr, Vesuna F, Raman V. Targeting host DEAD-box RNA helicase DDX3X for treating viral infections. Antiviral Res 2021;185:104994. [PMID: 33301755 DOI: 10.1016/j.antiviral.2020.104994] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Feuillet V, Canard B, Trautmann A. Combining Antivirals and Immunomodulators to Fight COVID-19. Trends Immunol 2021;42:31-44. [PMID: 33281063 DOI: 10.1016/j.it.2020.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
32 Felicetti T, Manfroni G, Cecchetti V, Cannalire R. Broad-Spectrum Flavivirus Inhibitors: a Medicinal Chemistry Point of View. ChemMedChem 2020;15:2391-419. [PMID: 32961008 DOI: 10.1002/cmdc.202000464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Xu Y, Jiang H. Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase. Protein Cell 2020;11:699-702. [PMID: 32761523 DOI: 10.1007/s13238-020-00769-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
34 Otręba M, Kośmider L, Rzepecka-Stojko A. Antiviral activity of chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine towards RNA-viruses. A review. Eur J Pharmacol 2020;887:173553. [PMID: 32949606 DOI: 10.1016/j.ejphar.2020.173553] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
35 Ligat G, Goto K, Verrier E, Baumert TF. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatology Rep 2020;19:235-44. [DOI: 10.1007/s11901-020-00534-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
36 Ji X, Li Z. Medicinal chemistry strategies toward host targeting antiviral agents. Med Res Rev 2020;40:1519-57. [PMID: 32060956 DOI: 10.1002/med.21664] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]